Metanalysis of 39 studies, 15,673 pts with nail psoriasis = 100% improvement of the Nail Psoriasis Severity Index, ixekizumab was best @ 24 wks (OR 2.98; 95% CI, 1.74-5.10), followed by TNF inhibitor (infliximab, adalimumab). https://t.co/VnhbMPYEV7